Stock Track | TransMedics Group Soars 7.69% After Hours on Stellar Q2 Earnings, Raised Guidance

Stock Track

2025/07/31

Shares of TransMedics Group, Inc. (NASDAQ: TMDX) surged 7.69% in after-hours trading on Wednesday following the release of its impressive second-quarter 2025 financial results. The medical technology company, which specializes in organ transplant solutions, significantly outperformed analyst expectations, driving investor enthusiasm.

TransMedics reported quarterly earnings of $0.92 per share, dramatically surpassing the analyst consensus estimate of $0.44 by 111.01%. This represents a substantial 162.86% increase from the $0.35 per share reported in the same period last year. The company's total revenue for Q2 reached $157.4 million, marking a 38% year-over-year growth and beating the expected $147.9 million. Net income for the quarter stood at a robust $34.9 million.

Adding to the positive sentiment, TransMedics raised its full-year 2025 revenue guidance to a range of $585 million to $605 million, reflecting a 35% growth at the midpoint compared to the previous year. The company's President and CEO, Waleed Hassanein, expressed confidence in their strategy, emphasizing their focus on achieving 10,000 US NOP (National OCS Program) transplants by 2028. The strong financial performance, coupled with recent developments such as receiving conditional IDE approval for the Next-Gen OCS™ Lung trial and the launch of the OCS NOP digital ecosystem, underscores TransMedics' growth trajectory and market position in the advanced medical equipment and technology sector.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1140057061"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1140057061\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1140057061?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 04:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140057061","market":"nz","top_or_hot":-1,"title":"Stock Track | TransMedics Group Soars 7.69% After Hours on Stellar Q2 Earnings, Raised Guidance","media":"Stock Track","content":"<p>Shares of TransMedics Group, Inc. (NASDAQ: TMDX) surged 7.69% in after-hours trading on Wednesday following the release of its impressive second-quarter 2025 financial results. The medical technology company, which specializes in organ transplant solutions, significantly outperformed analyst expectations, driving investor enthusiasm.</p>\n\n<p>TransMedics reported quarterly earnings of $0.92 per share, dramatically surpassing the analyst consensus estimate of $0.44 by 111.01%. This represents a substantial 162.86% increase from the $0.35 per share reported in the same period last year. The company's total revenue for Q2 reached $157.4 million, marking a 38% year-over-year growth and beating the expected $147.9 million. Net income for the quarter stood at a robust $34.9 million.</p>\n\n<p>Adding to the positive sentiment, TransMedics raised its full-year 2025 revenue guidance to a range of $585 million to $605 million, reflecting a 35% growth at the midpoint compared to the previous year. The company's President and CEO, Waleed Hassanein, expressed confidence in their strategy, emphasizing their focus on achieving 10,000 US NOP (National OCS Program) transplants by 2028. The strong financial performance, coupled with recent developments such as receiving conditional IDE approval for the Next-Gen OCS™ Lung trial and the launch of the OCS NOP digital ecosystem, underscores TransMedics' growth trajectory and market position in the advanced medical equipment and technology sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TransMedics Group Soars 7.69% After Hours on Stellar Q2 Earnings, Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TransMedics Group Soars 7.69% After Hours on Stellar Q2 Earnings, Raised Guidance\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-07-31 04:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of TransMedics Group, Inc. (NASDAQ: TMDX) surged 7.69% in after-hours trading on Wednesday following the release of its impressive second-quarter 2025 financial results. The medical technology company, which specializes in organ transplant solutions, significantly outperformed analyst expectations, driving investor enthusiasm.</p>\n\n<p>TransMedics reported quarterly earnings of $0.92 per share, dramatically surpassing the analyst consensus estimate of $0.44 by 111.01%. This represents a substantial 162.86% increase from the $0.35 per share reported in the same period last year. The company's total revenue for Q2 reached $157.4 million, marking a 38% year-over-year growth and beating the expected $147.9 million. Net income for the quarter stood at a robust $34.9 million.</p>\n\n<p>Adding to the positive sentiment, TransMedics raised its full-year 2025 revenue guidance to a range of $585 million to $605 million, reflecting a 35% growth at the midpoint compared to the previous year. The company's President and CEO, Waleed Hassanein, expressed confidence in their strategy, emphasizing their focus on achieving 10,000 US NOP (National OCS Program) transplants by 2028. The strong financial performance, coupled with recent developments such as receiving conditional IDE approval for the Next-Gen OCS™ Lung trial and the launch of the OCS NOP digital ecosystem, underscores TransMedics' growth trajectory and market position in the advanced medical equipment and technology sector.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMDX","symbol_name":"Transmedics Group","start_time":0,"source_url":"","article_id":"1140057061","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140057061","pubTimestamp":1753907644,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of TransMedics Group, Inc. (NASDAQ: TMDX) surged 7.69% in after-hours trading on Wednesday following the release of its impressive second-quarter 2025 financial results. The medical technology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TMDX":"Transmedics Group"},"translate_title":"股票追踪|TransMedics Group盘后飙升7.69%，第二季度盈利出色，指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":1},"content_text":"Shares of TransMedics Group, Inc. (NASDAQ: TMDX) surged 7.69% in after-hours trading on Wednesday following the release of its impressive second-quarter 2025 financial results. The medical technology company, which specializes in organ transplant solutions, significantly outperformed analyst expectations, driving investor enthusiasm.\nTransMedics reported quarterly earnings of $0.92 per share, dramatically surpassing the analyst consensus estimate of $0.44 by 111.01%. This represents a substantial 162.86% increase from the $0.35 per share reported in the same period last year. The company's total revenue for Q2 reached $157.4 million, marking a 38% year-over-year growth and beating the expected $147.9 million. Net income for the quarter stood at a robust $34.9 million.\nAdding to the positive sentiment, TransMedics raised its full-year 2025 revenue guidance to a range of $585 million to $605 million, reflecting a 35% growth at the midpoint compared to the previous year. The company's President and CEO, Waleed Hassanein, expressed confidence in their strategy, emphasizing their focus on achieving 10,000 US NOP (National OCS Program) transplants by 2028. The strong financial performance, coupled with recent developments such as receiving conditional IDE approval for the Next-Gen OCS™ Lung trial and the launch of the OCS NOP digital ecosystem, underscores TransMedics' growth trajectory and market position in the advanced medical equipment and technology sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}